Story

Neurocrine Biosciences Stock Falls on Vykat Safety Concerns

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Neurocrine Biosciences Stock Falls on Vykat Safety Concerns
Text size
Background

Neurocrine Biosciences (NASDAQ: NBIX) shares fell 5.8% following a report detailing potential safety issues, including patient deaths, possibly linked to its drug Vykat, which is approved for treating Prader-Willi syndrome.

Details of the Safety Report

According to a Stat News report, a group of physicians and experts specializing in the rare disease has notified clinicians about a series of deaths and severe side effects among patients taking Vykat. The report cites data from the FDA's Adverse Event Monitoring System as of July 31, which includes:

  • 7 patient deaths
  • More than 100 serious adverse events

The group of experts emphasized that none of the deaths or side effects have been definitively linked to the drug and did not call for Vykat to be withdrawn from the market.

Company Response and Market Impact

Sample IUX Markets – In-articleAd

In response to the report, Neurocrine CEO Kyle Gano told Stat News, "We don’t see a relationship between the deaths and Vykat XR." Gano added that potential changes to the drug's label or updated instructions for physicians remain "on the table."

Vykat is a treatment for Prader-Willi syndrome, a genetic disorder characterized by a persistent and insatiable hunger. The safety concerns have introduced uncertainty for investors, prompting the significant single-day decline in the company's stock value.

Other Company Developments

Separately, Neurocrine announced positive results from its KINECT-PRO Phase 4 study of INGREZZA for the treatment of tardive dyskinesia. The study, which enrolled 59 patients, demonstrated that the drug improved patient-reported quality of life and functionality, as well as reduced the severity of movements over 24 weeks. The company stated that the safety and tolerability of INGREZZA were consistent with its known profile.

Read next

More on Stocks
Back to latest news

LATEST